These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1495889)

  • 21. A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder.
    Wilcox CS; Ryan PJ; Morrissey JL; Cohn JB; DeFrancisco DF; Linden RD; Heiser JF
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Oct; 18(6):979-93. PubMed ID: 7824763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate.
    Skoug JW; Borin MT; Fleishaker JC; Cooper AM
    Pharm Res; 1991 Dec; 8(12):1482-8. PubMed ID: 1808610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation.
    Fleishaker JC; Phillips JP; Eller MG; Smith RB
    J Clin Pharmacol; 1989 Jun; 29(6):543-9. PubMed ID: 2754023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Abbott TDx serum benzodiazepine immunoassay for the analysis of lorazepam, adinazolam, and N-desmethyladinazolam.
    Fraser AD; Bryan W
    J Anal Toxicol; 1995 Sep; 19(5):281-4. PubMed ID: 7500613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative bioavailability of oral sustained-release and regular-release oxprenolol tablets at steady-state.
    Gupta PK; Lim JK; Zoest AR; Lam FC; Hung CT
    Biopharm Drug Dispos; 1991 Oct; 12(7):493-503. PubMed ID: 1932612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gradient high performance liquid chromatographic assay for degradation products of adinazolam mesylate in a sustained release tablet formulation.
    Stemm NL; Skoug JW; Robins RH
    Pharm Res; 1995 May; 12(5):738-45. PubMed ID: 7479561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adinazolam sustained-release treatment of panic disorder: a double-blind study.
    Davidson JR; Beitman B; Greist JH; Maddock RJ; Lewis CP; Sheridan AQ; Carter C; Krishnan KR; Liebowitz MR; Haack DG
    J Clin Psychopharmacol; 1994 Aug; 14(4):255-63. PubMed ID: 7962681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?
    Kroboth PD; Folan MM; Bauer KS; Tullock W; Wright CE; Sweeney JA
    J Clin Pharmacol; 1998 Apr; 38(4):337-46. PubMed ID: 9590461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man.
    Wagner JG; Rogge MC; Natale RB; Albert KS; Szpunar GJ
    Biopharm Drug Dispos; 1987; 8(5):405-25. PubMed ID: 3663878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and pharmacodynamic evaluation of novel dual release formulations of triazolam.
    Smith RB; Kroboth PD; Folan MM; Kroboth FJ; Rosanske TW
    Int J Clin Pharmacol Ther Toxicol; 1993 Sep; 31(9):422-9. PubMed ID: 8225690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
    Wright CE; Sisson TL; Fleishaker JC; Antal EJ
    J Clin Pharmacol; 1997 Apr; 37(4):321-9. PubMed ID: 9115058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects.
    Im YJ; Jeon JY; Kim EY; Kim Y; Oh DJ; Yoo JS; Shin DH; Chae SW; Kim MG
    Clin Ther; 2015 Feb; 37(2):376-89. PubMed ID: 25618318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC.
    Fraser AD; Isner AF; Bryan W
    J Anal Toxicol; 1993; 17(7):427-31. PubMed ID: 8309217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T; Henney HR
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.